A. Serikoff
Astellas Pharma (United Kingdom)(GB)Astellas Pharma (Netherlands)(NL)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Cancer, Lipids, and Metabolism, Hormonal and reproductive studies, Prostate Cancer Diagnosis and Treatment
Most-Cited Works
- → Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial(2003)59 cited
- → A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE(2021)19 cited
- → Inhibition of bFGF and EGF-induced proliferation of 3T3 fibroblasts by extract of Pygeum africanum (Tadenan®)(1994)19 cited
- → Troubles vésicosphinctériens et syndrome métabolique(2012)10 cited
- → Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial(2024)10 cited
- → Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study(2025)5 cited
- → Permixon ® [Lipiod-sterolic extract of serenoa repens (LSESr)] Inhibits estrogen/androgen-induced prostate enlargment in the rat(1995)4 cited
- → Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings(2025)2 cited
- → Permixon ® [lipido sterolic extract of serenoa repens (LSESr)] inhibits b-FGF- and EGF-induced proliferation of human prostate organotypic cell lines(1995)2 cited
- → P130 Cardiovascular (CV) events and Overall Survival (OS) in Patients (pts) treated with Abiraterone Acetate (AA) Vs ENzalutamide (ENZA) for chemotherapy-naïve metastatic Castration Resistant Prostate Cancer (mCRPC) in GERmany: AVENGER study(2024)1 cited